{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:08:39Z","timestamp":1760242119491,"version":"build-2065373602"},"reference-count":29,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2018,12,29]],"date-time":"2018-12-29T00:00:00Z","timestamp":1546041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R21 AI113801"],"award-info":[{"award-number":["R21 AI113801"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Respiratory syncytial virus (RSV) is one of the leading causes of lower respiratory tract infection in infants. Immunoprophylaxis with the anti-RSV monoclonal antibody, palivizumab, reduces the risk for RSV-related hospitalizations, but its use is restricted to high-risk infants due to the high costs. In this study, we investigated if genetic delivery of anti-RSV antibody to neonatal mice by chimpanzee adenovirus type 7 expressing the murine form of palivizumab (AdC7\u03b1RSV) can provide protection against RSV. Intranasal and intramuscular administration of AdC7\u03b1RSV to adult mice resulted in similar levels of anti-RSV IgG in the serum. However, only intranasal administration resulted in detectable levels of anti-RSV IgG in the bronchoalveolar lavage fluid. Intranasal administration of AdC7\u03b1RSV provided protection against subsequent RSV challenge. Expression of the anti-RSV antibody was prolonged following intranasal administration of AdC7\u03b1RSV to neonatal mice. Protection against RSV was confirmed at 6 weeks of age. These data suggest that neonatal genetic delivery of anti-RSV antibody by AdC7\u03b1RSV can provide protection against RSV.<\/jats:p>","DOI":"10.3390\/vaccines7010003","type":"journal-article","created":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T07:22:30Z","timestamp":1546240950000},"page":"3","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Neonatal Genetic Delivery of Anti-Respiratory Syncytial Virus (RSV) Antibody by Non-Human Primate-Based Adenoviral Vector to Provide Protection against RSV"],"prefix":"10.3390","volume":"7","author":[{"given":"Rika","family":"Gomi","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Weill Cornell Medicine, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anurag","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Weill Cornell Medicine, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzhu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Weill Cornell Medicine, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Worgall","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Weill Cornell Medicine, New York, NY 10065, USA"},{"name":"Department of Genetic Medicine, Weill Cornell Medicine, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,12,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1016\/S2214-109X(17)30344-3","article-title":"Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): A retrospective case series","volume":"5","author":"Scheltema","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1413456","article-title":"Viral Bronchiolitis in Children","volume":"374","author":"Meissner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children","volume":"360","author":"Hall","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1016\/S0163-4453(17)30205-0","article-title":"Development of respiratory syncytial virus (RSV) vaccines for infants","volume":"74","author":"Gerretsen","year":"2017","journal-title":"J. Infect."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.coviro.2017.03.015","article-title":"Ongoing developments in RSV prophylaxis: A clinician\u2019s analysis","volume":"24","author":"Rezaee","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1016\/j.vaccine.2016.03.109","article-title":"Advances in RSV vaccine research and development\u2014A global agenda","volume":"34","author":"Higgins","year":"2016","journal-title":"Vaccine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1080\/21645515.2017.1337614","article-title":"Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection","volume":"13","author":"Resch","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what\u2019s important?","volume":"10","author":"Kobinger","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1016\/j.vaccine.2014.08.049","article-title":"Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection","volume":"32","author":"Sharma","year":"2014","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nri1394","article-title":"Neonatal adaptive immunity comes of age","volume":"4","author":"Adkins","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1038\/sj.gt.3302375","article-title":"Fetal and neonatal gene therapy: Benefits and pitfalls","volume":"11","author":"Waddington","year":"2004","journal-title":"Gene Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/1743-422X-8-375","article-title":"Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine","volume":"8","author":"Krause","year":"2011","journal-title":"Virol. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.virol.2008.04.016","article-title":"Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV","volume":"378","author":"Skaricic","year":"2008","journal-title":"Virology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0092-8674(92)90213-V","article-title":"In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium","volume":"68","author":"Rosenfeld","year":"1992","journal-title":"Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1128\/jvi.70.11.7498-7509.1996","article-title":"Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy","volume":"70","author":"Mittereder","year":"1996","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1086\/514115","article-title":"Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus","volume":"176","author":"Johnson","year":"1997","journal-title":"J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/AAC.01285-13","article-title":"A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults","volume":"57","author":"Robbie","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","unstructured":"(2018, November 26). Synagis\u00ae (Palivizumab). Available online: https:\/\/www.synagis.com."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.smim.2009.01.005","article-title":"Immune homeostasis in the respiratory tract and its impact on heterologous infection","volume":"21","author":"Wissinger","year":"2009","journal-title":"Semin. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1084\/jem.192.9.1317","article-title":"Influenza virus lung infection protects from respiratory syncytial virus-induced immunopathology","volume":"192","author":"Walzl","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Hua, X., Vijay, R., Channappanavar, R., Athmer, J., Meyerholz, D.K., Pagedar, N., Tilley, S., and Perlman, S. (2018). Nasal priming by a murine coronavirus provides protective immunity against lethal heterologous virus pneumonia. JCI Insight, 3.","DOI":"10.1172\/jci.insight.99025"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1073\/pnas.93.7.3056","article-title":"Successful expression of human factor IX following repeat administration of adenoviral vector in mice","volume":"93","author":"Walter","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/exmp.1995.1015","article-title":"Differential short-term transduction efficiency of adult versus newborn mouse tissues by adenoviral recombinants","volume":"62","author":"Huard","year":"1995","journal-title":"Exp. Mol. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/INF.0000000000001916","article-title":"Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants","volume":"37","author":"Domachowske","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Griffin, M.P., Khan, A.A., Esser, M.T., Jensen, K., Takas, T., Kankam, M.K., Villafana, T., and Dubovsky, F. (2017). Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.01714-16"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/7\/1\/3\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:36:38Z","timestamp":1760196998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/7\/1\/3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,29]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["vaccines7010003"],"URL":"https:\/\/doi.org\/10.3390\/vaccines7010003","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2018,12,29]]}}}